ArticleFrontiers in psychiatry2021
Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine.
Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Psychobiotics in Depression: Sources, Metabolites, and Treatment-A Systematic Review.Nutrients · 2025Pooled it
- Gut microbiota of patients with post-stroke depression in Chinese population: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression.Translational psychiatry · 2023Pooled it
- A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.Molecular psychiatry · 2022Pooled it
- Effects ofFrontiers in psychiatry · 2026Trial
- Novel insight into the effects of the metabolites from gut microbiota in both unmedicated depressive adolescents and mice: key roles of indole derivatives-aryl hydrocarbon receptor signaling in neurogenesis and microglial homeostasis.Molecular psychiatry · 2026Article
- Reproducible Gut Microbiome Alterations in Major Depressive Disorder: A Systematic Review of Taxonomic and Functional Findings.Epidemiologia (Basel, Switzerland) · 2026Review
- Ellagic acid can improve stroke by regulating gut microbiota.Metabolic brain disease · 2026Review
- Article
- Understanding the Connection Between the Gut-Brain Axis and Major Depression: A Theoretical Perspective.Advances in experimental medicine and biology · 2026Review
- A taxon-centered review of bacterial shifts in psychiatric disorders.Frontiers in psychiatry · 2026Review
- 16S rRNA Gene Amplicon Sequencing of Gut Microbiota in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
- The role of gut microbiome in the pathophysiology of PTSD, depression, and anxiety disorders.Gut microbes reports · 2026Review
- The Gut Microbiota Is Altered in Antidepressant-Free Depressed Patients and Is Associated With Depression Severity.Journal of neurochemistry · 2025Article
- Medication use is associated with distinct microbial features in anxiety and depression.Molecular psychiatry · 2025Article
- Electron-beam FLASH whole brain irradiation induced a unique changes of intestinal flora.Molecular medicine (Cambridge, Mass.) · 2025Article
- The Bidirectional Relationship Between the Gut Microbiome and Mental Health: A Comprehensive Review.Cureus · 2025Review
- The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?International clinical psychopharmacology · 2025Review
- The saNeuroGut Initiative: Investigating the Gut Microbiome and Symptoms of Anxiety, Depression, and Posttraumatic Stress.Neuroimmunomodulation · 2025Article
- Trends in research on novel antidepressant treatments.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vortioxetine hydrobromide is a common clinical medication for major depressive disorder (MDD). However, it remains unclear whether vortioxetine hydrobromide acts by affecting the structure and composition of gut microbiota. Here, we analyzed fecal samples from 28 healthy controls (HCs) and 26 patients with MDD before treatment with vortioxetine hydrobromide, at 4 weeks after treatment, and at 8 weeks after treatment. High-throughput pyrosequencing showed that, according to the Chao1 and Shannon indices, fecal bacterial α-diversity was higher in the patients with MDD than in the HCs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.